Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...
Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
Phase 1b/2 dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer. This is an ...
INSTALL results showed successful and safe non-viral insertion of large genetic payloads in the livers of mice when delivered by lipid nanoparticles (LNPs). In contrast, mice experienced fatal immune ...
In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
The FDA approved amivantamab (Rybrevant) plus combination chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) in patients whose tumors harbor EGFR exon 20 insertion ...
Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results